Enovis (ENOV) Competitors $30.60 -0.42 (-1.36%) Closing price 03:59 PM EasternExtended Trading$30.66 +0.07 (+0.22%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENOV vs. DOV, STVN, IRTC, GKOS, BLCO, TMDX, SLNO, NVST, LIVN, and WRBYShould you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Dover (DOV), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), and Warby Parker (WRBY). Enovis vs. Its Competitors Dover Stevanato Group iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Soleno Therapeutics Envista LivaNova Warby Parker Dover (NYSE:DOV) and Enovis (NYSE:ENOV) are related companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the media refer more to DOV or ENOV? In the previous week, Dover had 5 more articles in the media than Enovis. MarketBeat recorded 18 mentions for Dover and 13 mentions for Enovis. Dover's average media sentiment score of 1.52 beat Enovis' score of 1.42 indicating that Dover is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dover 16 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Enovis 8 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, DOV or ENOV? Dover has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Dover, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDover$7.75B3.22$2.70B$16.5810.95Enovis$2.11B0.83-$825.49M-$14.25-2.15 Do analysts recommend DOV or ENOV? Dover presently has a consensus target price of $213.92, suggesting a potential upside of 17.78%. Enovis has a consensus target price of $51.00, suggesting a potential upside of 66.68%. Given Enovis' stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Dover.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dover 0 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.58Enovis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in DOV or ENOV? 84.5% of Dover shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 1.3% of Dover shares are held by insiders. Comparatively, 2.7% of Enovis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is DOV or ENOV more profitable? Dover has a net margin of 29.29% compared to Enovis' net margin of -37.80%. Dover's return on equity of 18.19% beat Enovis' return on equity.Company Net Margins Return on Equity Return on Assets Dover29.29% 18.19% 9.86% Enovis -37.80%6.78%3.73% Which has more volatility & risk, DOV or ENOV? Dover has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. SummaryDover beats Enovis on 11 of the 16 factors compared between the two stocks. Get Enovis News Delivered to You Automatically Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENOV vs. The Competition Export to ExcelMetricEnovisMEDICAL INFO SYS IndustryMedical SectorNYSE ExchangeMarket Cap$1.77B$2.13B$5.78B$21.31BDividend YieldN/AN/A3.95%3.51%P/E Ratio-2.1537.4631.2629.34Price / Sales0.839.66454.1352.84Price / Cash1.6152.6337.7323.86Price / Book0.686.5910.045.39Net Income-$825.49M-$63.67M$3.27B$996.59M7 Day Performance3.95%3.23%3.17%3.12%1 Month Performance11.83%0.62%4.34%2.97%1 Year Performance-32.49%28.23%44.12%12.83% Enovis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENOVEnovis4.5371 of 5 stars$30.60-1.4%$51.00+66.7%-31.7%$1.77B$2.11B-2.157,367Positive NewsInsider TradeDOVDover4.9488 of 5 stars$180.53-1.4%$213.92+18.5%+0.2%$25.11B$7.75B10.8924,000Positive NewsSTVNStevanato Group1.7841 of 5 stars€21.99-2.8%N/A+9.2%€6.66B€1.19B40.725,521News CoveragePositive NewsIRTCiRhythm Technologies1.345 of 5 stars$165.68-2.0%$162.64-1.8%+149.9%$5.43B$591.84M-56.552,000Positive NewsAnalyst ForecastGKOSGlaukos4.7232 of 5 stars$91.78-2.5%$127.42+38.8%-29.5%$5.40B$383.48M-55.62780Analyst RevisionBLCOBausch + Lomb1.1889 of 5 stars$14.57-2.5%$15.56+6.8%-10.2%$5.29B$4.79B-18.6713,500TMDXTransMedics Group2.888 of 5 stars$114.97-4.1%$123.00+7.0%-33.3%$4.09B$441.54M59.57210Positive NewsAnalyst ForecastSLNOSoleno Therapeutics4.5705 of 5 stars$66.51-3.0%$115.09+73.0%+38.0%$3.64BN/A-16.0730News CoverageAnalyst ForecastNVSTEnvista3.6053 of 5 stars$21.15-2.6%$20.92-1.1%+13.6%$3.61B$2.51B66.1012,300Positive NewsLIVNLivaNova1.618 of 5 stars$56.35+0.8%$59.71+6.0%+21.2%$3.05B$1.25B-14.492,900Positive NewsWRBYWarby Parker2.1624 of 5 stars$26.18-3.1%$24.06-8.1%+72.7%$2.84B$771.32M-373.883,780Positive News Related Companies and Tools Related Companies Dover Competitors Stevanato Group Competitors iRhythm Technologies Competitors Glaukos Competitors Bausch + Lomb Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Envista Competitors LivaNova Competitors Warby Parker Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ENOV) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.